Status:

COMPLETED

Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia

Lead Sponsor:

FHI 360

Collaborating Sponsors:

Population Services International

Population Council

Conditions:

HIV

Eligibility:

MALE

18-49 years

Phase:

PHASE4

Brief Summary

The study will measure the incidence of moderate and severe adverse events (AEs) associated with PrePex procedures among 500 men, including both procedural and post-procedure events, and all device-re...

Detailed Description

The World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and other global reproductive health organizations have recognized the protective effect of male circumcision in...

Eligibility Criteria

Inclusion

  • Must be aged 18 to 49 years;
  • Must be uncircumcised (on examination);
  • Must be in good general health;
  • Must agree to voluntary counseling and testing for HIV, or have documentation of testing no more than one week before the MC visit;
  • Must be HIV-uninfected;
  • Must be free of genital ulcerations or other visible signs of STI (on examination);
  • Must be able to understand study procedures and the requirements of study participation;
  • Must agree to return to the healthcare facility for the full schedule of follow-up visits after his circumcision or be willing to receive a home visit;
  • Must freely consent to participate in the study and sign a written informed consent form;
  • Must have a cell phone or access to a cell phone; and,
  • Must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.

Exclusion

  • Penis does not fit any of the five PrePex sizes;
  • Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;
  • Has known bleeding/clotting disorder (e.g. hemophilia);
  • Has an active genital infection, anatomic abnormality (e.g. phimosis or hypospadias) or other disease or condition (e.g. extreme obesity, poorly controlled diabetes, sickle cell anemia, AIDS-like signs or symptoms) which in the investigator's opinion contraindicates MC or participation in the study; and,
  • Is participating in another longitudinal biomedical research study.

Key Trial Info

Start Date :

October 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2014

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT01844102

Start Date

October 1 2013

End Date

April 1 2014

Last Update

May 13 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Society for Family Health

Lusaka, Lusaka Province, Zambia